Jun 21, 2011
By:
Stephanie Sutton
GlaxoSmithKline (GSK) has entered into an agreement to purchase Shenzhen Neptunus' stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau. GSK will pay Shenzhen Neptunus $39 million, after which GSK will be the sole owner of the joint venture company, Shenzhen GSK-Neptunus Biologicals (GSKNB).
|
Jun 14, 2011
By:
Stephanie Sutton
Believing that transparency in the pricing of medicines is ?fundamental? to enabling patients and stakeholders to make proper decisions about equity and value for money in health systems, the European Public Health Alliance (EPHA) called for greater pricing transparency. EPHA also called for the formation of a public website that provides comparative information on medicines? procurement prices. EPHA?s calls are a response to the European Commission?s consultation on the possible revision of Directive 89/105/EEC, which concerns the transparency of the pricing and reimbursement of medicines in various member states.
|
Jun 7, 2011
By:
Stephanie Sutton
The pharmaceutical industry has been called to action by a new report that highlights the health and cost repercussions of patient noncompliance. According to Capgemini?s report, Patient Adherence: The Next Frontier in Patient Care, patient adherence to medications for chronic conditions, such as HIV and Arthritis, averages at only 50%.
|
May 24, 2011
By:
Stephanie Sutton
Amylin Pharmaceuticals has filed a lawsuit against Eli Lilly, alleging that Lilly is engaging in "anticompetitive activity" and "breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide." According to Amylin, Lilly is planning to jointly develop and commercialize a linagliptin product with Boehringer Ingelheim that will directly compete with Amylin?s exenatide products.
|
Apr 19, 2011
By:
Stephanie Sutton
J&J Announces Settlement for Corrupt Practices
|
Apr 5, 2011
By:
Stephanie Sutton
Biosimilars Market will be Worth $3.7 Billion by 2015
|
Dec 9, 2010
By:
Stephanie Sutton
China and India will become the world leaders in innovation during the next decade, according to an international survey released by AstraZeneca.
|
|
